ArticleStem cells international2026
The Use of Human Platelet Lysate (hPL) Enables 3D Cultivation of ADSCs Derived From Human Breast Tissue.
Article in Stem cells international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: For the application of mesenchymal stem cells (MSCs) in regenerative medicine, xeno-free ex vivo cultivation is necessary. Therefore, this study aimed to investigate whether adipose-derived stem cells (ADSCs) from human breast tissue could be cultivated with human platelet lysate (hPL)-a promising alternative derived from human platelets-instead of fetal bovine serum (FBS). Methods: The influence of hPL within the culture medium of ADSCs from the female breast was analyzed regarding immunophenotype, adipogenic differentiation capacity, growth kinetics, and cell cycle distribution of ADSCs. Subsequently, the formation of spheres in hPL-supplemented medium was characterized in detail. Results: In comparison to FBS, the supplementation of medium with hPL resulted in a change in morphology, but the immunophenotype remained unchanged. Furthermore, supplementation of the medium with hPL caused an improved adipogenic differentiation capacity, increased growth, and shortened population doubling time (PDT) in ADSCs. Additionally, the cultivation of ADSCs with hPL led to spontaneous formation of spheres. Conclusion: hPL is not only a replacement for the ethically controversial cell culture additive FBS but also offers a xeno-free method for the cultivation of breast tissue-derived ADSCs and thus represents an important step from bench to bedside.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.